Can-Fite BioPharma (CANF) Investor Update summary

Financial position and funding outlook

• Raised $5 million recently, with $4.7 million previously, providing funding for 16-18 months.

• Additional milestone payments from partners expected to further support operations.

• Over $20 million received from out-licensing deals, with $130 million in potential future milestone payments.

• No commitment to avoid further offerings in the next 12 months, but efforts will be made to minimize dilution.

Pipeline and clinical development

• Lead drug Piclidenoson in pivotal phase III for psoriasis, with patient enrollment starting soon.

• Namodenoson in phase III for advanced liver cancer and phase IIb for MASH; phase IIa for pancreatic cancer starting soon.

• Piclidenoson also being developed for osteoarthritis in pets, with positive preclinical results and a large market opportunity.

• All drugs are small molecule, orally bioavailable, and target the A3 adenosine receptor, showing high selectivity and safety.

Business development and partnerships

• Multiple out-licensing deals in Europe, China, Korea, Canada, and with Vetbiolix for animal health.

• Ongoing discussions with potential new partners, aiming for additional non-dilutive funding.

• Royalties expected from existing and future partnerships.